SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Spero Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.12+0.02 (+1.82%)
Close on Oct 19, 2026
- Market cap
- $64.92M
- P/E (TTM)
- 28.0
- Dividend yield
- –
Dividends
Spero Therapeutics has not reported a dividend
No dividend per share appears in Spero Therapeutics's annual filings since fiscal 2014.